SEC Form 4 · accession 0001209191-18-005421
Ultragenyx Pharmaceutical Inc. · RARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William Aliski
Director
Period of report
Jan 23, 2018
Accepted (ET)
Jan 25, 2018 · 5:07 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001515673
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 23, 2018 | M | 11,500 | $21.00 | A | 73,360 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F1 | $21.00 | Jan 23, 2018 | M | 11,500 | D | — | Jan 29, 2024 | Common Stock | 11,500 | 0 | D |
Explanation of responses
- F11/3 of the shares initially subject to the option vested one year from January 30, 2014 and then 1/36 of the shares initially subject to the option began vesting monthly thereafter.
Remarks
The shares acquired in connection with the option exercise are subject to a lock-up agreement that restricts the transfer of these shares. No shares are being sold by the Reporting Person.